GCG and Nephropathy: These clear effects (observed through comparison with various comparators, including current weekly GLP1-RAs on the market) are complemented by interesting data on cardiovascular safety and efficacy (from post-hoc studies) regarding the incidence and progression of nephropathy and hepatic steatosis.